Simon Jenkins

Simon Jenkins, PhD, joined Sermonix Pharmaceuticals as vice president of Operations in 2018. Simon has over 30 years of experience in global drug development leadership roles across a range of therapeutic areas, including asthma, inhalation device development, cardiovascular, menopausal health, osteoporosis, and oncology. He has a track record of regulatory approvals in the United States, Europe, and Japan.

In particular, at Wyeth/Pfizer, Dr Jenkins led the global regulatory development programs for bazedoxifene and CE/bazedoxifene (Duavee), working closely with Dr Barry Komm.

Simon has extensive experience leading cross-functional development teams through all aspects of drug development to which he brought strong team and entrepreneurial skills to ensure team collaboration, effectiveness, and success.